Prostate Cancer Home > Xtandi and Breastfeeding
It is unknown if Xtandi (enzalutamide) passes through breast milk in women, or if it would harm a nursing infant. The manufacturer of the drug recommends that women not breastfeed during Xtandi treatment. However, this chemotherapy drug is approved to treat prostate cancer in men and is not approved for use in women.
Can Breastfeeding Women Take Xtandi?
Xtandi® (enzalutamide) is a prescription medicine approved to treat advanced prostate cancer that is resistant to treatments used to reduce testosterone levels. At this time, it is unknown if the medicine passes through breast milk. However, Xtandi is not approved for use in women.
More Information on Xtandi and Breastfeeding
No research has been done on using Xtandi while breastfeeding. Therefore, it is unknown if the drug passes through breast milk, or if it would harm a nursing infant. The manufacturer recommends Xtandi not be used in breastfeeding women due to the potential for serious side effects in a nursing child.
It is important to note that medications are rarely studied in breastfeeding women, as this could expose an infant, who will not directly benefit from the drug, to possible side effects. In addition, Xtandi is only approved for use in men and would likely not be studied in women at all.
Talking With Your Healthcare Provider
If you are a woman and your healthcare provider has recommended Xtandi, you should talk to him or her about the potential risks of using this drug while breastfeeding. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision that is right for you.